Pricing
  1. JP-listed companies
  2. Carna Biosciences, Inc.
  3. Financials
  4. Effective tax rate (%)

Carna Biosciences, Inc. (4572)

Market cap
¥7.4B
P/E ratio
-3.5x
Karna Bioscience develops kinase inhibitor drugs and provides drug discovery support services to pharmaceutical companies and research institutions.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndEffective tax rate (%) (Million JPY)YoY (%)
Dec 31, 2025-0.1-60.96%
Dec 31, 2024-0.2-88.71%
Dec 31, 2023-2-4.23%
Dec 31, 2022-2+441.28%
Dec 31, 2021-0.4-52.40%
Dec 31, 2020-0.8-108.96%
Dec 31, 20198.9-2821.06%
Dec 31, 2018-0.3-40.36%
Dec 31, 2017-0.5+137.17%
Dec 31, 2016-0.2-103.81%
Dec 31, 20156-2048.76%
Dec 31, 2014-0.3

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat